Moors & Cabot Inc. Sells 5,950 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Moors & Cabot Inc. decreased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) by 20.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 23,275 shares of the company’s stock after selling 5,950 shares during the period. Moors & Cabot Inc.’s holdings in Elanco Animal Health were worth $284,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ELAN. Cary Street Partners Investment Advisory LLC lifted its stake in shares of Elanco Animal Health by 257.2% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,854 shares of the company’s stock valued at $35,000 after acquiring an additional 2,055 shares during the last quarter. Signaturefd LLC lifted its stake in shares of Elanco Animal Health by 97.4% in the 3rd quarter. Signaturefd LLC now owns 3,306 shares of the company’s stock valued at $41,000 after acquiring an additional 1,631 shares during the last quarter. Eisler Capital UK Ltd. bought a new stake in shares of Elanco Animal Health in the 3rd quarter valued at about $46,000. UMB Bank n.a. lifted its stake in shares of Elanco Animal Health by 26.9% in the 4th quarter. UMB Bank n.a. now owns 3,747 shares of the company’s stock valued at $46,000 after acquiring an additional 795 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Elanco Animal Health by 381.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 4,229 shares of the company’s stock valued at $52,000 after acquiring an additional 3,350 shares during the last quarter.

Wall Street Analyst Weigh In

ELAN has been the subject of a number of recent analyst reports. Piper Sandler lowered their price target on Elanco Animal Health from $15.00 to $12.00 in a research report on Thursday, March 2nd. Morgan Stanley decreased their target price on Elanco Animal Health from $20.00 to $19.00 and set an “equal weight” rating for the company in a research report on Monday, January 30th. Finally, Barclays raised Elanco Animal Health from an “equal weight” rating to an “overweight” rating and set a $14.00 target price for the company in a research report on Thursday, April 20th. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $16.50.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, Director R David Hoover purchased 10,000 shares of the firm’s stock in a transaction on Friday, March 3rd. The shares were acquired at an average cost of $11.13 per share, with a total value of $111,300.00. Following the completion of the acquisition, the director now directly owns 155,000 shares in the company, valued at $1,725,150. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director R David Hoover bought 10,000 shares of Elanco Animal Health stock in a transaction dated Friday, March 3rd. The shares were purchased at an average cost of $11.13 per share, with a total value of $111,300.00. Following the completion of the acquisition, the director now owns 155,000 shares of the company’s stock, valued at approximately $1,725,150. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jeffrey N. Simmons bought 15,000 shares of Elanco Animal Health stock in a transaction dated Friday, March 10th. The stock was purchased at an average cost of $9.60 per share, for a total transaction of $144,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 45,000 shares of the company’s stock, valued at approximately $432,000. The disclosure for this purchase can be found here. 6.40% of the stock is owned by company insiders.

Elanco Animal Health Price Performance

Shares of ELAN opened at $8.51 on Monday. The business’s fifty day simple moving average is $9.20 and its two-hundred day simple moving average is $11.36. The company has a current ratio of 2.25, a quick ratio of 1.24 and a debt-to-equity ratio of 0.75. Elanco Animal Health Incorporated has a 12 month low of $8.48 and a 12 month high of $24.93.

Elanco Animal Health (NYSE:ELAN – Get Rating) last released its quarterly earnings results on Tuesday, May 9th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.16. The firm had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.18 billion. Elanco Animal Health had a positive return on equity of 8.21% and a negative net margin of 0.49%. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period last year, the business posted $0.36 EPS. On average, equities analysts expect that Elanco Animal Health Incorporated will post 0.8 earnings per share for the current year.

Elanco Animal Health Company Profile

(Get Rating)

Elanco Animal Health, Inc innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine.